Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M MacDonald

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Journal of Hypertension|April 1, 2011
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronismHari K Parthasarathy, Joel Ménard, William B White, et al.
Heart (British Cardiac Society)|February 21, 2014
High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based studyMaheshwar Pauriah, Douglas H J Elder, Simon Ogston, et al.
BMJ Open|August 9, 2015
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trialThomas M MacDonald, Bryan Williams, Mark Caulfield, et al.
Eclinicalmedicine|May 22, 2024
Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) studyFilippo Pigazzani, Kenneth A Dyar, Steve V Morant, et al.
Lancet (London, England)|September 29, 2015
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialBryan Williams, Thomas M MacDonald, Steve Morant, et al.
European Heart Journal Open|December 11, 2024
Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug usersRicky Vaja, Plinio Ferreira, Laura Portas, et al.
Therapeutic Advances in Neurological Disorders|January 28, 2025
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status updateKerstin Hellwig, Melinda Magyari, Thomas M MacDonald, et al.
The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Journal of Hypertension|April 1, 2011
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronismHari K Parthasarathy, Joel Ménard, William B White, et al.
Heart (British Cardiac Society)|February 21, 2014
High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based studyMaheshwar Pauriah, Douglas H J Elder, Simon Ogston, et al.
BMJ Open|August 9, 2015
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trialThomas M MacDonald, Bryan Williams, Mark Caulfield, et al.
Eclinicalmedicine|May 22, 2024
Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) studyFilippo Pigazzani, Kenneth A Dyar, Steve V Morant, et al.
Lancet (London, England)|September 29, 2015
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialBryan Williams, Thomas M MacDonald, Steve Morant, et al.
European Heart Journal Open|December 11, 2024
Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug usersRicky Vaja, Plinio Ferreira, Laura Portas, et al.
Therapeutic Advances in Neurological Disorders|January 28, 2025
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status updateKerstin Hellwig, Melinda Magyari, Thomas M MacDonald, et al.
The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Pageof 16